OpGen to restart following new venture round

After laying off most of its staff earlier this year during a cash crunch, Madison, WI-based OpGen has received a $23.6 million shot in the arm that will allow the biotech to "restart" operations. The fresh start comes with a commitment to find a new CEO to run the company. Last spring the company laid off two thirds of its 17-person staff. OpGen uses optical mapping technology to identify microorganisms and plans to expand its work identifying bacteria and fungi so that doctors can prescribe the right antibiotics. CHL Medical Partners, Highland Capital Partners and Versant Ventures jointly led the round.

- check out this release on the round

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.